BASIC AND CLINICAL STUDIES ON CS-807

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement1; pp. 395 - 403
• Main Authors: KOIDE, JUN, TOHGOH, TOSHITO, AMAGAI, RIEKO, TOYODA, TAKEO, OKUI, SHINJI, HOMMA, SATOKI, FUJITA, TAKANORI, KAWAI, MIEKO, ABE, TOHRU, TAKASHI, KOHTAROH, KURISHIMA, SETSUKO, YUHARA, TAKAMICHI, FUKUI, TOSHIO, KATSU, MASATAKA, MIZUKOSHI, KAZUO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement1_395

Basic and clinical studies were performed on CS-807, a newly developed cephalosporin for oral use. The MICs of R-3763 for 285 strains of 17 species of clinical isolates were compared with those of AMPC, AMPC-CVA and CCL. The antibacterial activity of R-3763 against S. aureus was as high as that of CCL and those of S. pneumoniae and S. pyogenes were comparable to those of AMPC and AMPC-CVA and higher than that of CCL. Against all gram-negative bacilli studied, antibacterial activity of R-3763 was the highest. In the clinical studies, a daily dose of 200-400mg of CS-807 administered b.i.d.was given orally for 7-23 days to 18 patients including 16 cases with respiratory tract infections and 2 cases with urinary tract infections. The clinical efficacy rate was 88.2% on 17 patients excluding 1 case who took CS-807 only 1 day because of vertigo. As side-effects, vertigo was observed in 1 case as stated above. BR>As abnormal laboratory findings related to CS-807, slightly elevated s-GOT, s-GPT and s-Al-P were observed in 1 case and basophilia was observed in 1 case. In conclusion, CS-807 is an effective antibiotic in the treatment of respiratory tract infections.